Table 1.
Clinical Features of the Study Population.
| Patient No. | Age (yr) | Treatment Regimens | Receptor Status | Tumor Grade | Excised Tumor Size (cm) | Pathologic Response | ||
| ER | PR | HER2 | ||||||
| 1 | 50 | AC → Taxol* | + | + | - | 3 | 0.5 | Residual disease |
| 2 | 52 | Taxotere† | + | - | + | 3 | 1.5 | Residual disease |
| 3 | 60 | AC → Taxol + concurrent trastuzumab | + | + | + | 1 | 2.9 | Residual disease |
| 4 | 36 | Taxol + cisplatin ± everolimus† | - | - | - | 2 | 2.9 | Residual disease |
| 5 | 48 | Dose-dense AC → Taxol | + | + | - | 1 | 1.3 | Residual disease |
| 6 | 43 | Dose-dense AC → Taxol | + | + | - | 2 | 2.6 | Residual disease |
| 7 | 59 | Dose-dense AC → Taxol | + | + | - | 2 | 4.2 | Residual disease |
| 8 | 53 | Taxol + cisplatin ± everolimus | - | . | - | 2 | 1.3 | Residual disease |
| 9 | 35 | Trastuzumab + carboplatin + ixabepilone | + | + | + | 3 | 1.4 | Residual disease |
| 10 | 28 | Taxol + cisplatin ± everolimus | - | - | - | 3 | 0.8 | Residual disease |
| 11 | 33 | AC → Taxol | + | + | - | 3 | 1.2 | Residual disease |
| 12 | 39 | AC → Taxol | + | + | - | 1 | 2.5 | Residual disease |
| 13 | 57 | AC → Taxol | - | - | - | 3 | N/A§ | Residual disease |
| 14 | 67 | Dose-dense AC → Taxol | - | - | + | 3 | 1.8 | Residual disease |
| 15 | 45 | Taxol + cisplatin ± everolimus | - | - | - | 3 | 0.5 | Residual disease |
| 16 | 46 | Taxotere + carboplatin + Herceptin¶ | + | + | + | 3 | 0.3 | Residual disease |
| 17 | 47 | Taxotere → AC | + | + | - | 1 | 8.0 | Residual disease |
| 18 | 36 | AC → Taxol | + | + | + | 2 | 1.0 | Residual disease |
| 19 | 43 | Cisplatin + Taxol ± everolimus | - | - | + | 3 | 0.7 | Residual disease |
| 20 | 55 | AC → Taxol | + | + | - | 2 | 3.5 | Residual disease |
| 21 | 58 | Cisplatin + Taxol ± everolimus | - | + | - | 2 | 1.7 | Residual disease |
| 22 | 53 | AC → concurrent Taxol + trastuzumab | - | - | + | 3 | 0 | pCR |
| 23 | 46 | Taxotere → AC | - | + | - | 3 | 0 | pCR |
| 24 | 46 | AC → concurrent Taxol + trastuzumab | - | - | + | 2 | 0 | pCR |
| 25 | 33 | AC → weekly Taxol | - | - | - | 3 | 0 | pCR |
| 26 | 39 | Trastuzumab and Lapatinib | - | - | + | 2 | 0 | pCR |
| 27 | 46 | AC → Taxol | + | - | - | 3 | 0 | pCR |
| 28 | 42 | Taxol + cisplatin ± everolimus | - | - | - | 3 | 0 | pCR |
| 29 | 34 | Taxotere → AC | - | - | - | 3 | 0 | pCR |
| 30 | 44 | Trastuzumab + Lapatinib | - | - | + | 3 | 0 | pCR |
| 31 | 37 | Taxol + cisplatin ± everolimus | - | - | - | 3 | 0 | pCR |
| 32 | 39 | AC → Taxol | - | - | - | 3 | 0 | pCR |
| 33 | 48 | Taxotere + carboplatin + Herceptin | - | - | + | 3 | 0 | pCR |
AC indicates adriamycin and cyclophosphamide; HER2, human epidermal growth factor receptor 2.
*
paclitaxel (Taxol; HQ SPCLT PHARMA, Paramus, NJ).
†
docetaxel (Taxotere; Sanofi-Aventis, Bridgewater, NJ).
‡
The study is ongoing, and we are blinded to the randomization.
§
This patient was transferred to another hospital, and the tumor size is not available.
¶
trastuzumab (Herceptin; Genentech Inc, San Francisco, CA).